Endothelin receptor antagonist
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
A endothelin receptor antagonist (ERA) is a drug which blocks endothelin receptors.
Two main kinds of ERAs exist:
- selective ERA (e.g. sitaxsentan), which affect endothelin A.
- dual ERAs,(e.g. bosentan) which affect both endothelin A and B .[1]
See also
References